HanAll's Licensed Partner Entered into an Exclusive Sublicense Agreement with CSPC NBP Pharma for Batoclimab
Shots:
- Harbour BioMed to receive ~$139.5M incl. $20.93M up front along with the milestones. The collaboration will accelerate batoclimab's clinical development & will launch in China in multiple indications
- NBP Pharma gets an exclusive right to develop & commercialize batoclimab in Greater China incl. mainland of China, Hong Kong, Macau, and Taiwan. HanAll's focused on ophthalmology, immunology, oncology & neurology to develop innovative therapies for patients with diseases
- HL161BKN (batoclimab) is currently in the P-III & P-II trials for rare autoimmune disorders incl. MG, TED, warm AIHA, NMO, and ITP while HL036 is an anti-TNF alpha protein drug & is being studied in the P-III trials in the US & China for dry eye disease
Ref: PRNewswire | Image: HanAll
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
